Did You Know?

Editor’s Picks

Latest News

A Historic Leap Toward Curing Heart Disease: New Study Shows Cavadex Dramatically Reverses Symptoms and Restores Quality of Life in High-Risk Patients

Groundbreaking Observational Study Reveals 88% of Participants Experienced Significant Health Improvements, Offering Unprecedented Hope in the Fight Against the World's...

A Historic Leap Toward Curing Heart Disease: New Study Shows Cavadex Dramatically Reverses Symptoms and Restores Quality of Life in High-Risk Patients

Groundbreaking Observational Study Reveals 88% of Participants Experienced Significant Health Improvements, Offering Unprecedented Hope in the Fight Against the World's...

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every...

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved...

Alira Health Becomes First Platinum CRO Partner of the Wound Care Collaborative Community, Expanding Ongoing Work to Advance Wound Healing Innovation

FRAMINGHAM, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Alira Health announced today that it has become the first Platinum CRO...

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology...

error: Content is protected !!